KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) Invested Capital (2016 - 2025)

Pacira BioSciences has reported Invested Capital over the past 16 years, most recently at $1.1 billion for Q4 2025.

  • Quarterly results put Invested Capital at $1.1 billion for Q4 2025, down 21.88% from a year ago — trailing twelve months through Dec 2025 was $1.1 billion (down 21.88% YoY), and the annual figure for FY2025 was $1.1 billion, down 21.88%.
  • Invested Capital for Q4 2025 was $1.1 billion at Pacira BioSciences, down from $1.1 billion in the prior quarter.
  • Over the last five years, Invested Capital for PCRX hit a ceiling of $1.5 billion in Q4 2022 and a floor of $749.6 million in Q3 2024.
  • Median Invested Capital over the past 5 years was $1.0 billion (2024), compared with a mean of $1.0 billion.
  • Biggest five-year swings in Invested Capital: soared 116.63% in 2021 and later decreased 29.64% in 2023.
  • Pacira BioSciences' Invested Capital stood at $888.3 million in 2021, then soared by 64.87% to $1.5 billion in 2022, then dropped by 4.91% to $1.4 billion in 2023, then fell by 2.08% to $1.4 billion in 2024, then dropped by 21.88% to $1.1 billion in 2025.
  • The last three reported values for Invested Capital were $1.1 billion (Q4 2025), $1.1 billion (Q3 2025), and $1.3 billion (Q2 2025) per Business Quant data.